Leerink Partners Raises Vaxcyte (NASDAQ:PCVX) Price Target to $153.00

Vaxcyte (NASDAQ:PCVX) had its target price hoisted by Leerink Partners from $106.00 to $153.00 in a research note published on Tuesday, Benzinga reports. They currently have an outperform rating on the stock.

Other equities research analysts have also issued research reports about the stock. Needham & Company LLC upped their price target on shares of Vaxcyte from $95.00 to $140.00 and gave the company a buy rating in a research report on Tuesday. BTIG Research upped their target price on shares of Vaxcyte from $98.00 to $160.00 and gave the company a buy rating in a report on Tuesday. Finally, Cantor Fitzgerald reiterated an overweight rating on shares of Vaxcyte in a research note on Thursday, June 20th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of Buy and a consensus target price of $131.83.

Vaxcyte Trading Up 2.7 %

NASDAQ:PCVX opened at $112.10 on Tuesday. The company has a market cap of $12.20 billion, a PE ratio of -26.19 and a beta of 0.97. The company has a 50 day simple moving average of $81.08 and a two-hundred day simple moving average of $73.28. Vaxcyte has a 12 month low of $44.20 and a 12 month high of $119.27.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($1.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.12). During the same quarter in the prior year, the firm posted ($0.70) earnings per share. Research analysts forecast that Vaxcyte will post -4.33 earnings per share for the current year.

Insider Buying and Selling

In related news, SVP Elvia Cowan sold 5,000 shares of the company’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $107.67, for a total value of $538,350.00. Following the completion of the transaction, the senior vice president now owns 12,723 shares of the company’s stock, valued at approximately $1,369,885.41. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, SVP Elvia Cowan sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $107.67, for a total value of $538,350.00. Following the transaction, the senior vice president now directly owns 12,723 shares of the company’s stock, valued at approximately $1,369,885.41. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Grant Pickering sold 15,000 shares of the stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $75.64, for a total transaction of $1,134,600.00. Following the sale, the chief executive officer now directly owns 478,888 shares of the company’s stock, valued at $36,223,088.32. The disclosure for this sale can be found here. In the last ninety days, insiders sold 85,283 shares of company stock valued at $7,271,218. 3.10% of the stock is owned by corporate insiders.

Institutional Trading of Vaxcyte

Institutional investors and hedge funds have recently bought and sold shares of the stock. Goldman Sachs Group Inc. increased its position in Vaxcyte by 12.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 481,119 shares of the company’s stock worth $30,214,000 after purchasing an additional 52,005 shares during the last quarter. Natixis Advisors L.P. bought a new position in shares of Vaxcyte in the 4th quarter valued at about $881,000. Vestal Point Capital LP purchased a new position in Vaxcyte in the fourth quarter worth about $32,970,000. Harbor Capital Advisors Inc. increased its stake in Vaxcyte by 392.4% during the second quarter. Harbor Capital Advisors Inc. now owns 40,342 shares of the company’s stock worth $3,046,000 after acquiring an additional 32,149 shares during the last quarter. Finally, TD Asset Management Inc raised its position in Vaxcyte by 10.5% during the fourth quarter. TD Asset Management Inc now owns 167,036 shares of the company’s stock valued at $10,490,000 after purchasing an additional 15,890 shares during the period. 96.78% of the stock is currently owned by institutional investors.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.